It will be slow going for the Trump administration’s regulatory reform agenda if FDA’s decision to withdraw a direct final rule on inspection scheduling for biologic drug products is any indication.
FDA cites “significant adverse comment” in a May 7 Federal Register notice for its decision to withdraw the direct final...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?